Search Results for: peripheral t-cell lymphoma

December 12, 2019December 12, 2019

Health Canada Approves Adcetris-Chemo Combo for Initial Peripheral T-cell Lymphoma Treatment

News

Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval is ... Read more

November 14, 2018

Verastem Advances Copiktra for Peripheral T-cell Lymphoma Under LLS Therapy Acceleration Program

News

Aiming to accelerate the development of Copiktra (duvelisib) for treatment of peripheral T-cell lymphoma (PTCL) — an aggressive type of non-Hodgkin’s lymphoma — Verastem has announced a collaboration with the Leukemia & Lymphoma Society (LLS). ... Read more

November 9, 2018

Seattle Genetics Seeks Adcetris Approval as First-Line Combo Treatment for Peripheral T-cell Lymphomas

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment for patients with ... Read more

October 8, 2018

Portola’s Cerdulatinib Wins Orphan Drug Designation for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Portola Pharmaceuticals‘ investigative therapy cerdulatinib to treat patients with peripheral T-cell lymphoma (PTCL), the company announced. Orphan drug designation aims to encourage therapies for ... Read more

August 22, 2018

FDA Grants CPI-613 Orphan Drug Status For Peripheral T-Cell Lymphoma Treatment

News

Therapeutic candidate CPI-613, developed by Rafael Pharmaceuticals, received orphan drug designation by the U.S. Food and Drug Administration for the treatment of peripheral T-cell lymphoma (PTCL). This is the fifth ... Read more

June 11, 2018

First-line GEM-P Chemo Fails to Improve Response Rates in Peripheral T-cell Lymphomas, Results Show

News

The GEM-P chemotherapy regimen composed of gemcitabine, Platinol (cisplatin), and the corticosteroid methylprednisolone failed to improve response rates of peripheral T-cell lymphoma patients who have not received prior treatment, according to Phase 2 trial results. ... Read more

April 20, 2018

Patients with Peripheral T-cell Lymphoma Resistant to First-Line Therapy Show Worse Outcomes, Study Finds

News

Patients with peripheral T-cell lymphomas receiving standard treatment have worse outcomes if they are not responsive to first-line therapy, a prospective study shows. Bone marrow transplants undertaken after these therapies have ... Read more

December 18, 2017

Rhizen’s Tenalisib Receives FDA Fast Track Status for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the tenalisib (RP6530), Rhizen Pharmaceuticals‘ PI3K delta/gamma blocker, for the treatment of patients with relapsed or refractory peripheral ... Read more

December 11, 2017

Aptevo to Launch Phase 2 Trial of Therapy Candidate for Peripheral T-cell Lymphoma

News

Aptevo Therapeutics, a biotech company developing new therapies for blood and lymph cancers, will soon launch a Phase 2 clinical trial to evaluate its monospecific antibody candidate, otlertuzumab, in patients ... Read more

May 12, 2017May 12, 2017

Managed Access Program to Provide European Peripheral T-cell Lymphoma Patients Access to Beleodaq

News

Europeans with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have no current alternative treatment options may soon get access to Onxeo‘s Beleodaq (belinostat), under a managed access program lauched by ... Read more